SCHEMBL3432205

SCHEMBL3432205

CS(=O)(=O)c1ccc(Cn2nc(C(=O)Nc3ccc4c(c3)OCO4)c3ccccc32)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.51
USP2 O75604 3/20 0.51
TSHR P16473 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
ATM Q13315 2/20 0.51
ELANE P08246 1/20 0.51
NPC1 O15118 6/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 1/20 0.49
NPY1R P25929 1/20 0.48
NPY2R P49146 1/20 0.48
MAPT P10636 4/20 0.47
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
POLB P06746 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
IDH1 O75874 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3426277 0.95 RAB9A (0.57) RAB9AUSP2NPC1KMT2AMEN1
SCHEMBL3430712 0.92 RAB9A (0.52) RAB9AUSP2TSHRNPSR1ATM
SCHEMBL13051112 0.91 IDH1 (0.54) RAB9AUSP2TSHRNPSR1ATM
SCHEMBL3430842 0.91 RAB9A (0.49) RAB9AUSP2TSHRNPSR1ATM
SCHEMBL3427388 0.91 RAB9A (0.49) RAB9AUSP2TSHRNPSR1ATM
SCHEMBL3428179 0.91 RAB9A (0.49) RAB9AUSP2TSHRNPSR1ATM
SCHEMBL3749208 0.90 MAPT (0.45) RAB9AUSP2ATMNPC1KMT2A
SCHEMBL3430664 0.89 RAB9A (0.56) RAB9AUSP2TSHRNPSR1ATM
SCHEMBL3427905 0.89 MAPT (0.56) RAB9AUSP2TSHRNPSR1ATM
SCHEMBL3406432 0.89 RAB9A (0.61) RAB9AUSP2TSHRNPSR1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO claimed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 RAB9A 2878/4885USP2 2684/4885TSHR 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.